Eric Jia-Sobota, Founder

The Department of Commerce’s CHIPS (Creating Helpful Incentives to Produce Semiconductors) Program Office has garnered significant attention from potential investors and stakeholders across the United States. With a focus on expanding semiconductor production capabilities in the country, the CHIPS Program Office has already received over 300 statements of interest (SOIs) from various applicants representing 37

DTRA Funding Alert: Amendment to DTRA Chemical / Biological Technologies Broad Agency Announcement Includes Additional Funding Opportunities to Develop Bioinformatics Capabilities, Ocular Sampling Technologies, and MCMs for Chemical Warfare Agents On March 21, 2023, the Defense Threat Reduction Agency (DTRA) released an amendment to the current Broad Agency Announcement (BAA) seeking proposals that address the

New Funding Opportunities Available Through the New Advanced Research Projects Agency for Health (ARPA-H) BAA ARPA-H, or the Advanced Research Projects Agency for Health, is an agency within the National Institutes of Health (NIH) that aims to accelerate the development of breakthrough technologies and treatments for major diseases. ARPA-H has been likened to the Defense

Amendment to BAA Outlines New DTRA Funding Opportunities to Develop Novel Technologies and Medical Countermeasures Against Weapons of Mass Destruction (WMD) and Emerging Threats The Defense Threat Reduction Agency (DTRA) recently published an amendment to their Broad Agency Announcement (‘BAA”) No. HDTRA1-22-S-0003, which provides additional funding opportunities to identify and counter Weapons of Mass Destruction

New Strategy Leads to New Funding Opportunities for the Development of Medical Countermeasures In the wake of the Coronavirus Disease 2019 (COVID-19) pandemic and a rapidly expanding landscape of biological and chemical threats, the Department of Defense (DoD) is initiating a new approach to developing Medical Countermeasures (MCM) for Joint Force protection. The Office of

EverGlade Consulting (“EverGlade”), a national consulting firm, has helped a leading biotechnology company land an award from the Biomedical Advanced Research and Development Authority (BARDA) with a potential $1 billion in federal funding. This multi-year contract will allow the Company to advance the development of a full portfolio of innovative solutions to address influenza and

President Biden recently launched the administration’s new National Biodefense Strategy and Implementation Plan. The strategy reflects changing dynamics in Washington, especially given the lack of additional funding for COVID.  National BiodefenseStrategy and Implementation Summarized The plan calls for $88B in additional funding over 5 years and is focused on the following goals: Detect pandemics and